Vivoryon Therapeutics NV
AEX:VVY
Vivoryon Therapeutics NV
AEX:VVY
Price:
1.35
EUR
2.27%
Market Closed
Market Cap:
€40m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vivoryon Therapeutics NV
Total Current Liabilities
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Vivoryon Therapeutics NV
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vivoryon Therapeutics NV
AEX:VVY
|
Total Current Liabilities
€1.4m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-11%
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Total Current Liabilities
€2.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Total Current Liabilities
€72.3m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Total Current Liabilities
€43m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Total Current Liabilities
€160.1m
|
CAGR 3-Years
12%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Formycon AG
XETRA:FYB
|
Total Current Liabilities
€33.9m
|
CAGR 3-Years
48%
|
CAGR 5-Years
52%
|
CAGR 10-Years
28%
|
|
No Stocks Found
Vivoryon Therapeutics NV
Glance View
The company is headquartered in Halle, Sachsen-Anhalt and currently employs 16 full-time employees. The company went IPO on 2014-10-27.
VVY
Intrinsic Value
Not Available
See Also
What is Vivoryon Therapeutics NV's Total Current Liabilities?
Total Current Liabilities
1.4m
EUR
1.4m
EUR
Based on the financial report for Dec 31, 2024, Vivoryon Therapeutics NV's Total Current Liabilities amounts to 1.4m EUR.
What is Vivoryon Therapeutics NV's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
-11%
-11%
Over the last year, the Total Current Liabilities growth was -56%. The average annual Total Current Liabilities growth rates for Vivoryon Therapeutics NV have been -35% over the past three years , 9% over the past five years , and -11% over the past ten years .
